SYNE2 and breast cancer: We demonstrated significantly reduced expression of SUN1, SUN2, and nesprin-2 proteins in breast cancer (SUN1, 88%; SUN2, 74%; nesprin-2, 79%) regardless of clinicopathological classification (Table2) and all patients exhibited reduced expression of at least one of four components.